Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients.

× No keyword cloud information.

11 in total

1. Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

Authors: Nicolai Grønne Jørgensen; Shamaila Munir Ahmad; Niels Abildgaard; Per Thor Straten; Inge Marie Svane; Mads Hald Andersen; Lene Meldgaard Knudsen
Journal: Stem Cell Investig Date: 2016-12-23

Review 2. Tumor microenvironment antigens.

Authors: Mads Hald Andersen
Journal: Semin Immunopathol Date: 2022-09-29 Impact factor: 11.759

3. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.

Authors: Anders Friberg; Dominico Vigil; Bin Zhao; R Nathan Daniels; Jason P Burke; Pedro M Garcia-Barrantes; DeMarco Camper; Brian A Chauder; Taekyu Lee; Edward T Olejniczak; Stephen W Fesik
Journal: J Med Chem Date: 2012-12-17 Impact factor: 7.446

Review 4. Small molecule Mcl-1 inhibitors for the treatment of cancer.

Authors: Johannes Belmar; Stephen W Fesik
Journal: Pharmacol Ther Date: 2014-08-27 Impact factor: 12.310

5. Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.

Authors: Brandon Drennen; Jacob A Scheenstra; Jeremy L Yap; Lijia Chen; Maryanna E Lanning; Braden M Roth; Paul T Wilder; Steven Fletcher
Journal: ChemMedChem Date: 2016-02-04 Impact factor: 3.466

6. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.

Authors: Jason P Burke; Zhiguo Bian; Subrata Shaw; Bin Zhao; Craig M Goodwin; Johannes Belmar; Carrie F Browning; Dominico Vigil; Anders Friberg; DeMarco V Camper; Olivia W Rossanese; Taekyu Lee; Edward T Olejniczak; Stephen W Fesik
Journal: J Med Chem Date: 2015-04-17 Impact factor: 7.446

The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients.

1. Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

Review 2. Tumor microenvironment antigens.

3. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.

Review 4. Small molecule Mcl-1 inhibitors for the treatment of cancer.

5. Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.

6. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.

Review 7. The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.

8. BAG2 Overexpression Correlates with Growth and Poor Prognosis of Esophageal Squamous Cell Carcinoma.

9. Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.

10. How Good is Jarzynski's Equality for Computer-Aided Drug Design?